Related papers: OPTIMUS: Predicting Multivariate Outcomes in Alzhe…
Alzheimer's disease gradually affects several components including the cerebral dimension with brain atrophies, the cognitive dimension with a decline in various functions and the functional dimension with impairment in the daily living…
Alzheimer's disease (AD) is the most common neurodegenerative disease in older people. Despite considerable efforts to find a cure for AD, there is a 99.6% failure rate of clinical trials for AD drugs, likely because AD patients cannot…
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, structural brain changes, and genetic predispositions. This study leverages machine-learning and statistical techniques to investigate…
Alzheimer's disease (AD) is an incurable neurodegenerative condition leading to cognitive and functional deterioration. Given the lack of a cure, prompt and precise AD diagnosis is vital, a complex process dependent on multiple factors and…
Missing modalities pose a major issue in Alzheimer's Disease (AD) diagnosis, as many subjects lack full imaging data due to cost and clinical constraints. While multi-modal learning leverages complementary information, most existing methods…
Early detection of Alzheimer's disease's precursor stages is imperative for significantly enhancing patient outcomes and quality of life. This challenge is tackled through a semi-supervised multi-modal diagnosis framework. In particular, we…
Alzheimer's disease (AD) is a complex, multifactorial neurodegenerative disorder with substantial heterogeneity in progression and treatment response. Despite recent therapeutic advances, predictive models capable of accurately forecasting…
Alzheimer's disease (AD) is a prevalent and debilitating neurodegenerative disorder impacting a large aging population. Detecting AD in all its presymptomatic and symptomatic stages is crucial for early intervention and treatment. An active…
Automated methods for Alzheimer's disease (AD) classification have the potential for great clinical benefits and may provide insight for combating the disease. Machine learning, and more specifically deep neural networks, have been shown to…
In Alzheimer's disease (AD), the progressive atrophy leads to aberrant network reconfigurations both at structural and functional levels. In such network reorganization, the core and peripheral nodes appear to be crucial for the prediction…
Joint models for longitudinal and time-to-event data are commonly used in longitudinal studies to forecast disease trajectories over time. Despite the many advantages of joint modeling, the standard forms suffer from limitations that arise…
To study neurodegenerative diseases, longitudinal studies are carried on volunteer patients. During a time span of several months to several years, they go through regular medical visits to acquire data from different modalities, such as…
The aging population of the U.S. drives the prevalence of Alzheimer's disease. Brookmeyer et al. forecasts approximately 15 million Americans will have either clinical AD or mild cognitive impairment by 2060. In response to this urgent…
Mild cognitive impairment (MCI) conversion prediction, i.e., identifying MCI patients of high risks converting to Alzheimer's disease (AD), is essential for preventing or slowing the progression of AD. Although previous studies have shown…
Alzheimer s disease (AD) pathophysiology is still imperfectly understood and current paradigms have not led to curative outcome. Omics technologies offer great promises for improving our understanding and generating new hypotheses. However,…
Predicting stroke risk is a complex challenge that can be enhanced by integrating diverse clinically available data modalities. This study introduces a self-supervised multimodal framework that combines 3D brain imaging, clinical data, and…
Reliability in Neural Networks (NNs) is crucial in safety-critical applications like healthcare, and uncertainty estimation is a widely researched method to highlight the confidence of NNs in deployment. In this work, we propose an…
Disease modifying therapies for Alzheimer's disease demand precise timing decisions, yet current predictive models require longitudinal observations and provide no uncertainty quantification, rendering them impractical at the critical first…
Alzheimer's disease (AD) poses significant global health challenges due to its increasing prevalence and associated societal costs. Early detection and diagnosis of AD are critical for delaying progression and improving patient outcomes.…
The prediction of subjects with mild cognitive impairment (MCI) who will progress to Alzheimer's disease (AD) is clinically relevant, and may above all have a significant impact on accelerate the development of new treatments. In this…